Accepted for Publication: September 15, 2022.
Published Online: November 3, 2022. doi:10.1001/jamaophthalmol.2022.4567
Correction: This article was corrected on January 19, 2023, to add information about previously reported patients with monkeypox virus ophthalmic disease and update information based on public health reports.
Corresponding Author: Roberto Pineda II, MD, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, 243 Charles St, Boston, MA 02114 (roberto_pineda@meeei.harvard.edu).
Author Contributions: Dr Pineda had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: All authors.
Acquisition, analysis, or interpretation of data: Kaufman.
Drafting of the manuscript: Kaufman.
Critical revision of the manuscript for important intellectual content: All authors.
Administrative, technical, or material support: Kaufman.
Supervision: Chodosh, Pineda.
Conflict of Interest Disclosures: Dr Chodosh reported being a consultant to the US Food and Drug Administration, where he chairs an advisory committee for new ophthalmic medications; receiving grant support from the National Institutes of Health to study adenovirus keratitis; and receiving consultant fees from the US Food and Drug Administration outside the submitted work. Dr Pineda reported receiving royalties from Elsevier, personal fees from the data monitoring committees of Sanofi-Genzyme and Amgen, and consultant fees from Alcon outside the submitted work. No other disclosures were reported.
Funding/Support: This work was supported by a Heed Fellowship awarded by the Heed Ophthalmic Foundation (Dr Kaufman).
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.